Assessment of bone fragility and prediction of osteoporotic fracture risk using a quantitative determination of circulating under-carboxylated osteocalcin.

摘要

The invention relates to a method for the assessment of bone fragility and osteoporosis fracture risk characterised by : measuring in vitro the concentration of under-carboxylated osteocalcin in a biological fluid sample such as serum, plasma or urine ; comparing the concentration of under-carboxylated osteocalcin in the test sample with the concentration in a control sample containing levels of under-carboxylated osteocalcin representative of the upper limit of the normal range, concentrations above this upper limit being indicative of increased risk of bone fracture. t